Side-by-side · Research reference

HGH Fragment 176-191vsOxytocin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED28/59 cited

BFDA-ApprovedHUMAN-REVIEWED11/51 cited

HGH Fragment 176-191

GH Fragment · Pre-Clinical

50%Weight gain reductionNg 2000

~26 minHalf-life (est.)

No IGF-1 ↑GH axis impact

SQ · IP (animal) · Oral (tested)

Oxytocin

Neuropeptide Hormone · FDA-Approved

24–48 IUIntranasal dose (research)Prinsen 2026 Burmester 2025

~3–20 minPlasma half-life

9 AAPeptide length

Intranasal · IV (obstetric)

01Mechanism of Action

Parameter

HGH Fragment 176-191

Oxytocin

Primary target

Beta-3 adrenergic receptors on adipocytesHeffernan 2001

Oxytocin receptors (OXTR) — hypothalamus, amygdala, hippocampus, ventral tegmental area

Pathway

Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001

OXTR activation → Gq/11-coupled signaling → modulation of GABAergic, dopaminergic, serotonergic pathways → enhanced synaptic plasticity, neurogenesis, emotional regulation

Downstream effect

Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation

Social bonding enhancement, trust behavior, gaze modulation, reciprocal eye contact, anti-inflammatory and antioxidant neuroprotection, reduced amygdala threat responsePaul 2026 Prinsen 2026 Yuan 2026

Feedback intact?

N/A — does not interact with GH/IGF-1 axis

Yes — endogenous oxytocin-mediated feedback via central and peripheral OXTR pathways

Origin

Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015

Endogenous 9-amino-acid peptide synthesized in hypothalamic paraventricular and supraoptic nuclei, released from posterior pituitaryPaul 2026

Antibody development

Not reported in available studies

—

02Dosage Protocols

Parameter

HGH Fragment 176-191

Oxytocin

Animal dose (oral)

500 mcg/kg body weightNg 2000

Obese Zucker rats, 19 days.

—

Animal dose (IP)

Not specified (14-day chronic administration)Heffernan 2001

Obese mice, daily IP injection.

—

Human equivalent dose

Not established — no published human RCTs

—

Frequency

Once daily (animal models)

—

Evidence basis

Animal studies only

—

Duration tested

14–19 daysHeffernan 2001 Ng 2000

—

Detection window

50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015

WADA-banned; anti-doping testing available.

—

Oral bioavailability

Demonstrated efficacy in animal oral administrationNg 2000

Potential for oral therapeutic development.

—

Intranasal (research — autism, social cognition)

—

24–48 IUPrinsen 2026 Burmester 2025

Single dose; chronic dosing protocols vary (4–12 weeks documented).

Frequency (research)

—

Once daily to twice daily

IV (obstetric — labor induction)

—

0.5–2 mU/min, titrated every 30–60 min

FDA-approved Pitocin protocol; maximum 20–40 mU/min per institutional guidelines.

Evidence basis (social cognition)

—

Phase 1–2 RCTs in ASD, schizophrenia, social anxiety

Evidence basis (obstetric)

—

FDA-approved · standard-of-care

Duration (research protocols)

—

4–12 weeks chronic administrationPrinsen 2026

Half-life

—

~3–20 min (plasma); CNS effects persist longer

Timing (intranasal)

—

Morning or pre-social interaction

Acute effects within 30–90 minutes.

03Metabolic / Fat Loss Evidence

Parameter

HGH Fragment 176-191

Oxytocin

Primary fat target

Adipose tissue (general) — beta-3 AR mediated lipolysisHeffernan 2001

—

Weight gain reduction

50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000

Obese Zucker rats, 19 days oral administration.

—

Body fat reduction

Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001

—

Lipolytic activity

Increased adipose tissue lipolytic activityNg 2000

Direct measurement in treated animals.

—

Beta-3 AR expression

Upregulated β3-AR mRNA in obese mice to lean-comparable levelsHeffernan 2001

—

Insulin sensitivity

No adverse effect — euglycemic clamp confirmedNg 2000

Contrasts with intact hGH diabetogenic effects.

—

IGF-1 impact

No elevation — fragment does not activate GH/IGF-1 axis

—

Beta-3 AR dependency

Effect abolished in β3-AR knockout miceHeffernan 2001

Confirms β3-AR as primary mechanism.

—

Route of administration

Efficacy demonstrated via oral and IP routesNg 2000 Heffernan 2001

—

Human evidence

None published — pre-clinical only

—

04Side Effects & Safety

Parameter

HGH Fragment 176-191

Oxytocin

Insulin sensitivity

No adverse effects observed in euglycemic clamp (animal)Ng 2000

—

GH/IGF-1 axis

No activation — avoids diabetogenic effects of full GHNg 2000

—

Human safety data

Not available — no published human trials

—

WADA status

Banned as performance-enhancing drugCox 2015

—

Metabolic profile

Six metabolites identified; CRSVEGSCG most stableCox 2015

Detection window implications for doping control.

—

Nasal irritation (intranasal)

—

Mild dryness, congestion

Headache

—

Occasional, transient

Uterine hyperstimulation (IV obstetric)

—

Tachysystole, fetal distress — requires continuous monitoring

Negative interpretation bias (adolescents)

—

Increased negative interpretations of ambiguous social scenarios in female adolescents (with and without eating disorders)Burmester 2025

Hyponatremia (IV)

—

Water intoxication risk with prolonged high-dose IV infusion

Hypersensitivity

—

Rare allergic reactions

Individual variability

—

Salivary oxytocin levels show high subgroup variability in ASD populations; no consistent group-level differences vs controls in some studiesYılmazer 2025

Absolute Contraindications

HGH Fragment 176-191

·Competitive athletes (WADA-banned)Cox 2015

Oxytocin

·Fetal distress or abnormal fetal heart rate patterns (obstetric)
·Cephalopelvic disproportion
·Hypersensitivity to oxytocin

Relative Contraindications

HGH Fragment 176-191

·Absence of human safety data — experimental use only

Oxytocin

·Severe cardiovascular disease (obstetric use)
·Hypertonic or hyperactive uterus
·Prior uterine surgery or cesarean section (relative — use cautiously)

05Administration Protocol

Parameter

HGH Fragment 176-191

Oxytocin

1. Route

Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.

Administer 24–48 IU (typically 3–6 puffs per nostril) using nasal spray device. Patient should be seated, head tilted slightly forward. Avoid sniffing deeply; allow passive absorption.

2. Frequency

Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.

Administer 30–90 minutes before anticipated social interaction or cognitive assessment. Acute effects peak within 30–60 minutes.

3. Duration

Animal protocols: 14–19 days. Human duration not established — no published trials.

Dilute oxytocin 10 units in 1000 mL isotonic saline. Initiate at 0.5–2 mU/min via infusion pump. Titrate every 30–60 minutes based on contraction pattern and fetal heart rate. Continuous electronic fetal monitoring required.

4. Storage

Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.

Store at 2–8 °C (refrigerated). Do not freeze. Protect from light. Discard if solution is discolored or contains precipitate.

5. Detection

Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015

Chronic administration protocols (4–12 weeks) documented in pediatric ASD populations. Daily or twice-daily intranasal administration. Safety profile in chronic use still under investigation.